CSL Ltd Investor Briefing Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Stanton - Jefferies - Analyst : Thanks very much team, and good morning and good evening to everyone. Look, I'd like to discuss the complete response from the FDA on garadacimab. I wonder if you could give us a little bit more color on that? Specifically whether there's another trial required and the scale of time of delay, it sounds to me like it might be nine months or could it be longer based on previous sort of updates that we might see this drug on the market. Thank you very much.

Question: David Stanton - Jefferies - Analyst : Thank you. And I guess my follow-up then is, one of your smaller peers in the Australian listed market, at least. Is that an issue and had to do another trial based on sterility of the mixing, I guess, of the manufacturing, I mean, there's no requirement for another clinical trial. I just want to make that clear at this stage.

Question: David Stanton - Jefferies - Analyst : Understood, thank you very much. I'll get back in the queue.